Drug news
RepliGen withdraws application at EMA for SecreFlo an agent for Pancreatic Imaging
EMA has been advised by RepliGen of its decision to withdraw its application for SecreFlo (synthetic secretin human) as an agent for magnetic resonance imaging to improve the detection of pancreatic duct abnormalities in patients with pancreatitis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.